GED Capital buys Eugin's business in Europe and Latin America and IVI RMA buys its North American business

MADRID, 8 Nov. (EUROPA PRESS) -

The investment firm GED Capital has bought the European and Latin American business of the assisted reproduction company Eugin from the German healthcare group Fresenius, while IVI RMA, a group specialized in reproductive medicine owned by KKR, has acquired the North American operations of Eugin, including the Boston IVF network of fertility clinics and Trio, based in Toronto, Canada.

Specifically, GED will take over Eugin's businesses in Spain, Italy, Sweden, Denmark, Latvia and Portugal and in Brazil, Argentina and Colombia.

These operations are contained within a sales process organized by Lazard, in which different private capital funds, mainly international, have shown interest.

The final closing of the transaction, for which no amounts have been provided, is subject to customary regulatory approvals.

The business acquired by GED, with a turnover of approximately 100 million euros, includes more than 35 clinics, as well as the central services based in the Barcelona headquarters from where the Eugin group is managed.

Founded in 1999, Eugin currently has 69 clinics spread across eleven countries and a staff of more than 1,700 employees.

According to GED Capital, the global assisted reproduction market is valued at approximately 8.9 billion euros and is expected to continue growing at annual rates close to 10% in the coming years.

"We are convinced that the acquisition of Eugin's European and Latin American perimeter will be a great investment. It is an excellent growth platform, with great brand recognition and prestige, within a clearly expanding activity such as reproduction assisted," highlighted Enrique Centelles Satrústegui, managing partner of GED Capital.

This acquisition is the seventh operation of the GED VI Spain Fund and the third within the health sector, after the investments in the biotechnology company Vitro and the 'build up' carried out in the clinical trials company Evidenze.

For its part, IVI RMA has highlighted in a statement that the purchase of Eugin's business in North America will make the company "a leading fertility group" in the region.

"We are delighted to welcome Boston IVF, its partner clinics and Trio to the IVI RMA network to continue bringing scientific excellence in fertility to more markets in North America," said Javier Sánchez Prieto, CEO of IVI RMA.

This purchase will add more than 600 employees across 13 laboratories and 32 satellite offices to IVI RMA's network of 10 laboratories and 29 satellites in North America, bringing the organization's total employee count to more than 4,400 globally.

In addition, Boston IVF has multiple academic affiliations, such as Harvard Medical School, Dartmouth Hitchcock Medical School, Boston University Medical Center, or Tufts Medical Center, among others.

"Adding these respected fertility brands to the IVI RMA family is an important milestone for our industry and a great benefit to the patients we serve," added Lynn Mason, CEO of IVI RMA America.